Previous in vivo and in vitro experiments have indicated that PGE2 release stimulates APP expression via EP2/EP4 receptors in parallel with Aβ deposition, ultimately resulting in AD pathogenesis31. This evidence concerns the gene APP and Alzheimer disease.